The Mannitol Problem: Why some NAD+ therapies fall short

Mannitol as a Barrier to Intracellular Uptake of NAD+ During Intravenous Administration

Mechanistic Insights, ROS and Inflammation Correlations, and Mannitol-Free Therapeutic Alternatives

Abstract 

Nicotinamide adenine dinucleotide (NAD+) is a universal coenzyme essential for mitochondrial energy metabolism, genomic maintenance, and redox regulation. As people age, NAD+ levels decline significantly, contributing to mitochondrial dysfunction, oxidative stress, reduced DNA repair, and loss of cellular resilience [1–5]. Intravenous (IV) administration of NAD+ has been promoted as a strategy to rapidly replenish systemic pools. Clinical evidence, however, highlights a puzzling disconnect: plasma NAD+ can rise sharply after infusion, yet intracellular benefits often fall short.

A frequently overlooked factor in this discrepancy is the stabilizing excipient mannitol, which is commonly added to NAD+ formulations. Mannitol protects NAD+ against degradation during storage, yet it introduces physiological barriers in vivo. By increasing extracellular osmolarity, dehydrating and stiffening membranes, and tightening endothelial junctions, mannitol traps NAD+ outside the cell. This extracellular accumulation exposes NAD+ to rapid enzymatic degradation, blunting its therapeutic potential.

The paradox is greatest in individuals with chronic inflammation and oxidative stress—precisely the populations most in need of NAD+ restoration. This paper explores the mechanistic ways in which mannitol impedes NAD+ uptake, the compounding effects of reactive oxygen species (ROS) and inflammatory signaling, the mismatch between plasma and intracellular benefits, and why mannitol-free formulations represent a more biologically compatible therapeutic option.

Introduction

NAD+ plays a dual and indispensable role in biology. It functions as a redox cofactor in glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation, where it shuttles electrons to sustain ATP production. It also serves as a substrate for critical enzymes such as sirtuins, PARPs, and CD38, which regulate DNA repair, gene expression, epigenetic stability, and immune signaling [2,7].

Declining NAD+ levels are a hallmark of aging and chronic disease, contributing to fatigue,

neurodegeneration, metabolic dysfunction, and a progressive decline in cellular homeostasis [1,3,5]. Oral precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can modestly elevate circulating metabolites, but due to poor bioavailability and first-pass metabolism, they often fail to restore tissue NAD+ to functional levels [9].

IV infusion of NAD+ has therefore emerged as an appealing direct approach. It bypasses digestion, rapidly elevates plasma levels, and is marketed as a powerful tool for energy, recovery, and longevity. Yet despite strong rises in circulating NAD+, clinical outcomes remain mixed: intracellular markers of mitochondrial health, DNA repair, and sirtuin activity do not always improve in parallel [4,22].

This discrepancy suggests that delivery and formulation matter as much as dosage. The stabilizer mannitol, while chemically protective, has biological effects that hinder cellular uptake. Understanding this paradox is critical for translating IV NAD+ therapy into real clinical impact.

Mannitol’s Dual Role: Protector and Obstacle

Mannitol is widely used in pharmaceutical sciences as a bulking agent and cryoprotectant. In neurology, it serves as an osmotic diuretic to reduce intracranial pressure and cerebral edema [10]. In NAD+ formulations, it prevents aggregation and stabilizes the compound during lyophilization and storage.

However, the very properties that make mannitol useful in the lab work against NAD+ uptake in the body. Mannitol is osmotically active but does not readily enter cells. When infused, it draws water out of cells into the extracellular space. This causes cell shrinkage, increases cortical tension, and stiffens membranes. As a result, nutrient transporters and endocytic pathways operate less efficiently [12,13].

At the vascular level, mannitol causes endothelial contraction and tightening of intercellular junctions. While this property is exploited in neurosurgery to transiently open the blood-brain barrier, in systemic circulation it has the opposite effect—reducing paracellular permeability [13]. Thus, NAD+ is effectively “locked out” of its target cells.

Mannitol therefore presents a paradox: it preserves NAD+ during manufacturing but blocks it from reaching its biological target inside the cell.

Mechanistic Insights: How Mannitol Blocks Uptake

The barrier created by mannitol operates across multiple biological levels:

• Cellular level: Hyperosmotic shrinkage elevates cortical stiffness and suppresses clathrin-mediated endocytosis, reducing NAD+ internalization [14].
• Molecular level: Mannitol structures extracellular water into hydration shells that slow diffusion. NAD+ lingers outside cells, where it is degraded by ectoenzymes like CD38 and CD73 [6,15].
• Vascular level: By tightening endothelial junctions, mannitol reduces transendothelial passage, confining NAD+ to the plasma compartment [12,13].

Taken together, these mechanisms explain why plasma NAD+ surges after infusion do not consistently translate into intracellular restoration.

ROS, Mannitol, and Intracellular NAD+ Uptake

Reactive oxygen species (ROS) are unavoidable byproducts of mitochondrial respiration, particularly at complexes I and III of the electron transport chain. At physiological levels, they act as signaling molecules regulating autophagy, hypoxia adaptation, and immune responses. In excess, however, ROS inflict oxidative stress, damaging lipids, proteins, and DNA (Kregel & Zhang, 2007 [16]).

NAD+ is a cornerstone of antioxidant defense. It supports NADPH production via dehydrogenases such as glucose-6-phosphate dehydrogenase and isocitrate dehydrogenase. NADPH then regenerates glutathione (GSH) and thioredoxin, which buffer ROS. It also enables PARP-driven DNA repair and sirtuin-mediated mitochondrial maintenance (Houtkooper et al., 2010 [17]).

Mannitol complicates this system. Although it can scavenge hydroxyl radicals, its effect is limited, extracellular, and transient (Halliwell & Gutteridge, 2015 [18]). The most damaging ROS arise inside mitochondria—beyond mannitol’s reach. At the same time, mannitol restricts NAD+ entry into cells, starving mitochondria of the cofactor needed to produce NADPH and defend against oxidative stress (Dmitrieva & Burg, 2011 [12]).

This creates a self-reinforcing cycle:
1. Mannitol limits NAD+ uptake, reducing NADPH and antioxidant defenses. 2. Mitochondrial ROS rise, damaging lipids and mtDNA.
3. Damaged membranes become stiffer, further reducing NAD+ entry.
4. Dysfunctional mitochondria generate more ROS, perpetuating the barrier.

This loop explains why individuals with high oxidative stress—such as older adults or people with diabetes and neurodegenerative disease—often show the weakest intracellular responses to IV NAD+ with mannitol present.

Inflammation, Mannitol, and NAD+ Uptake

Chronic inflammation, or inflammaging, is a hallmark of aging and disease (Franceschi & Campisi, 2014 [8]). Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) activate NF-κB and STAT3 signaling, upregulating CD38, a major NAD+-consuming ectoenzyme (Aksoy et al., 2006 [19]). When NAD+ is trapped extracellularly by mannitol, CD38 rapidly degrades it, accelerating depletion.

Inflammation also alters lipid composition in membranes, decreasing fluidity and impairing transporter activity (Calder et al., 2017 [20]). Endothelial cells contract and tighten under inflammatory signaling, further restricting permeability (Mehta & Malik, 2006 [21]). These effects overlap with mannitol’s osmotic stress, compounding the blockade.

At the mitochondrial level, inflammatory signaling drives excess ROS production, while low NAD+ disables repair and sirtuin activity (Grant et al., 2019 [3]; Chini et al., 2017 [15]). The combined effect of inflammation and mannitol is a destructive synergy:
• Mannitol traps NAD+ outside cells.

• Inflammation accelerates extracellular breakdown and stiffens membranes.
• Together, they starve mitochondria and nuclei of NAD+, sustaining oxidative injury and cellular decline.

This synergy explains why elderly and inflamed individuals often respond poorly to NAD+ IV therapy containing mannitol.

Clinical Implications

The mismatch between plasma NAD+ and intracellular benefit has profound implications. Clinical measurements often report plasma spikes as proof of efficacy, yet markers of intracellular function—sirtuin activation, PARP activity, mitochondrial respiration—remain unchanged [4,22].

Mannitol-containing formulations may therefore provide a misleading sense of success. For those with high oxidative or inflammatory burdens, outcomes are particularly poor. Moreover, mannitol’s osmotic load can stress the kidneys and vasculature, raising safety concerns for frail individuals (Kochanek et al., 2019 [10]).

NAD+ Without Bulking Agents Like Mannitol

A straightforward path to improved biological effectiveness is to deliver NAD+ without mannitol. Isotonic, physiologic formulations preserve hydration and membrane flexibility, enabling NAD+ to cross into cells.

Alternative stabilizers—such as trehalose, sucrose, or amino acids—maintain chemical stability without creating osmotic barriers [23,25]. Nanocarriers and liposomal formulations further enhance delivery, shielding NAD+ from extracellular degradation while facilitating intracellular access [24,26].

The benefits of mannitol-free formulations include:
• Improved cellular uptake.
• Reduced renal and vascular stress.
• Closer alignment between plasma levels and real intracellular benefits.

Conclusion

Mannitol highlights a central paradox: it protects NAD+ chemically but blocks it biologically. Through osmotic stiffening, slowed diffusion, endothelial tightening, and synergy with ROS and inflammation, mannitol explains why plasma surges after IV NAD+ do not guarantee intracellular benefit.

Reformulating NAD+ in mannitol-free, physiologic solutions offers a practical way to unlock its full potential—allowing the coenzyme to restore cellular energy, genomic maintenance, and resilience in aging and disease.

References

1. Chini EN. CD38 as a regulator of cellular NAD. Curr Pharm Des. 2009;15(1):57–63. 

2. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141.

3. Grant R, Nguyen S, Guillemin GJ. NAD+ metabolism and neuroinflammation. Cells. 2019;8(7):702.

4. Yoshino J, Baur JA, Imai S. NAD+ intermediates and therapeutic potential. Cell Metab. 2018;27(3):513–528.

5. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208–1213.

6. Camacho-Pereira J et al. CD38 dictates age-related NAD decline. Nat Metab. 2019;1:195–209.

7. Nikiforov A, Dölle C, Niere M, Ziegler M. NAD biosynthesis pathways. Front Biosci. 2011;16:307–314.

8. Franceschi C, Campisi J. Chronic inflammation as a hallmark of ageing. Nat Rev Immunol. 2014;14:450–462.

9. Mills KF et al. Long-term NMN administration. Cell Metab. 2016;24(6):795–806.
10. Kochanek PM et al. Intravenous mannitol therapy. Lancet Neurol. 2019;18:654–666.

11. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+. Cell Metab. 2010;12(1):31–44.

12. Dmitrieva NI, Burg MB. Hypertonic stress response. Physiol Rev. 2011;91:1535–1582.

13. Rapoport SI. Osmotic opening of the BBB. Ann Neurol. 2000;48:231–239.

14. Sheetz MP, Dai J. Cell membrane mechanics. Trends Cell Biol. 1996;6:285–289.

15. Chini CC, Tarragó MG, Chini EN. NAD and ageing. Mol Cell Endocrinol. 2017;455:62–74.

16. Kregel KC, Zhang HJ. Oxidative stress in aging. Am J Physiol. 2007;292:R18–R36.

17. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+. Cell Metab. 2010;12(1):31–44.

18. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford Univ. Press; 2015.

19. Aksoy P, White TA, Thompson M, Chini EN. Regulation of CD38. Biochem Biophys Res Commun. 2006;345:1386–1392.

20. Calder PC et al. Inflammatory cytokines and membrane composition. J Nutr. 2017;147(7):1251–1265.

21. Mehta D, Malik AB. Endothelial permeability. Physiol Rev. 2006;86:279–367.

22. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules. Nat Rev Drug Discov. 2018;17:681–699.

23. Mensink MA et al. How sugars protect proteins. J Control Release. 2017;248:71–85.

24. Pinho E et al. Nanocarrier strategies for NAD+ delivery. Drug Deliv Transl Res. 2020;10:733–746.

25. Clegg JR et al. Stable polymer excipients for biologics. Adv Drug Deliv Rev. 2021;171:50–67.

26. Kang H et al. Liposomal strategies for NAD+ therapeutics. Int J Pharm. 2022;613:121391.

Author’s Note

The talks around NAD+ therapy are often dominated by enthusiasm, but important details like formulation are rarely considered. Mannitol, though useful for stabilizing compounds, can unintentionally limit the benefits people hope to receive. By bringing attention to this overlooked issue, my aim is to make complex science more accessible and relevant to those who seek healthier, longer lives.

I believe progress in longevity will not only come from breakthroughs, but also from refining the small details—removing barriers, improving delivery and therapeutical results, and aligning science with real human needs. NAD+ therapy has the potential to become a cornerstone of cellular health and longevity, provided we give it the best chance to work inside the body.

Author: Henry Gertjan van de Glind

Publishing date: 10 October 2025